DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
http://www.nasdaq.com.
Clovis Oncologyʼs Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial.
Online:
http://www.nasdaq.com/press-release/clovisoncologys-rucaparib-significantlyimprovedprogression-free-survival-in-allovariancancer-20170619-00122 Stand: 14.07.2017
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.